Iambic Therapeutics Raises $150 Million in IPO to Fund AI-Designed Cancer Drugs

Iambic Therapeutics priced its initial public offering late Wednesday, selling more than 9.37 million shares at $16 apiece, the midpoint of its targeted range. Shares began trading Thursday on the Nasdaq under the ticker "IAM," raising roughly $150 million for a company betting that artificial intelligence can shorten the distance between molecular design and clinical approval.

The San Diego-based firm is one of a growing cohort of techbio companies making AI the organizing principle of drug discovery rather than a peripheral tool. Iambic's platform, which it calls molecular superintelligence, pairs AI models with automated high-throughput experiments. Each test result feeds back into the system, sharpening predictions and search strategy over time. The company describes this as a continuous loop spanning everything from hit identification to clinical developability.

That pitch has already found paying customers. Iambic counts AbbVie, Bayer, Jazz Pharmaceuticals, Lundbeck, Revolution Medicines, and Takeda Pharmaceutical among its strategic partners. Collaboration revenue reached $12.7 million in the first half of this year, more than triple the $3.9 million reported over the same period in 2025. That growth rate matters. It suggests pharma partners are willing to pay more, not less, for access to the platform as it matures.

The Pipeline Behind the Raise

Iambic's lead asset, IAM1363, targets HER2, a cancer protein with a crowded competitive field that already includes antibodies, antibody drug conjugates, and oral small molecules. The company's bet is differentiation, not discovery of new biology. IAM1363 is designed to be selective across multiple HER2 variants, to penetrate the brain where HER2-driven tumors frequently metastasize, and to overcome drug resistance while limiting dose-related toxicity. Iambic attributes all of these design features to its AI platform.

The drug is currently in Phase 1/1b testing in patients with advanced or metastatic solid tumors carrying HER2 alterations. Iambic has said it expects to start a registrational trial as early as next year, a timeline that would compress the usual path from early-stage data to a pivotal study. That is an aggressive target for a company barely two years removed from emerging out of stealth.

Behind IAM1363 sit two earlier programs. IAM217, a KIF18A inhibitor, and IAM-C1, a dual CDK2/4 inhibitor, are both advancing toward clinical testing. Neither has the data maturity of the HER2 asset, and both will require their own trial results before investors can assess whether Iambic's platform generalizes across mechanisms or whether IAM1363 was a favorable case.

Iambic plans to spend $75 million to complete IAM1363's Phase 1 trial and launch one or more Phase 2 studies that could support an application for accelerated FDA approval. IAM217 and IAM-C1 will each receive about $15 million for their Phase 1/2 work. A further $20 million is budgeted for continued investment in the underlying AI technology itself, a line item that underscores how much of the company's long-term value proposition rests on the platform staying competitive.

Founded in 2019 by CEO Tom Miller, a former Caltech chemistry professor, and Chief Technology Officer Fred Manby, a former University of Bristol chemistry professor, Iambic developed its core technology in partnership with Nvidia, which also holds an equity stake in the company. The firm went public with its approach in 2023, disclosing $100 million in funding alongside an early look at its preclinical pipeline. Private fundraising has been substantial since then, totaling $536.5 million, including a $100 million round announced roughly a year ago.

Ownership following the IPO remains concentrated. Catalio Capital Management holds an 8.9% stake, the largest among shareholders, with Nexus Ventures close behind at 6.8%, according to the IPO filing. That concentration is typical for a recently private biotech but worth watching as lockup periods expire and early investors decide whether to hold or trim positions.

As of the end of the second quarter, Iambic reported $207.8 million in cash. Combined with IPO proceeds, the company expects that runway to extend into the fourth quarter of 2028, giving it roughly two years to generate the clinical data that will determine whether its platform claims hold up in practice.

What Investors Should Watch

Iambic's thesis rests on a single, testable claim: that better technology produces better medicines, and that doing so systematically can reduce the cost, time, and failure rate that have long plagued drug development. The company said as much directly in its IPO filing, framing the platform as something to be proven "program after program."

That framing cuts both ways for investors. A single successful registrational trial for IAM1363 would validate the approach and likely reprice the stock meaningfully higher, especially given the brain-penetrant positioning against a target already well understood by regulators and oncologists. But a stumble, whether in toxicity, efficacy, or trial design, would raise harder questions about whether AI-driven discovery genuinely outperforms conventional medicinal chemistry or simply moves faster to the same outcomes.

Miller himself has acknowledged the platform's moving target. In a 2023 interview, he noted that AI in drug discovery is "an incredibly fast-moving field" and that remaining differentiated requires ongoing innovation years out. That is an honest assessment, and it means the $20 million earmarked for platform investment is not optional spending but a competitive necessity against rivals making similar claims.

With roughly two years of funded runway and three programs advancing through early clinical stages, Iambic has bought itself time rather than certainty. The IPO proceeds buy the company room to generate data. Whether that data justifies the molecular superintelligence framing, or simply adds Iambic to the long list of AI drug discovery companies still waiting for a definitive clinical win, will be the question that shapes the stock's trajectory into 2028.